Study of How Rectal Cancer Responds to Standard Chemoradiation and Chemotherapy Before Surgery

What this Trial Is About

Researchers are studying how people with rectal cancer respond to standard treatments like chemoradiation and chemotherapy before surgery. The purpose is to understand how the body reacts to these treatments and whether testing blood, tissue, and scans can help predict if the cancer improves, worsens, or stays the same after treatment. This study is sponsored by Memorial Sloan Kettering Cancer Center and focuses on participants with invasive adenocarcinoma of the rectum. Participants will receive standard-of-care neoadjuvant therapy, which includes chemoradiation with induction fluoropyrimidine drugs such as capecitabine or 5-FU, followed by plans for consolidative chemotherapy regimens like CAPEOX, FOLFOX, or FOLIRINOX. Standard endoscopy is used as part of the diagnostic testing during treatment. These treatments and procedures are part of the usual care for rectal cancer, monitored closely within this study. During the study, participants will have tests on their blood, tissue, and scans at different times to help researchers observe the cancers response to treatment. The main outcome measured is clinical response, which will be followed for up to three years. Participants are monitored for safety and treatment effects throughout this period, with all data collected helping to improve understanding of treatment responses in rectal cancer.

A Study of Response to Standard Treatment Before Surgery in People With Rectal Cancer